Antiviral agents

Abstract

This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals, as well as novel intermediates useful in the preparation of the compounds of formula I.

1. A compound of formula IV: 
       
         
           
           
               
               
           
         
       
       or a salt thereof, wherein:
 R 1  is hydrogen, C 1-4 alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, mono or di(C 1-4 alkyl)amino, cyano, formyl, —CH═NO—C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxyC 1-4 alkoxy, C 1-4 haloalkoxy, aryloxy, C 1-4 alkylthio, or aryl; 
 A is a bond or CH 2 O; 
 Y is O, S, NH or NMe; 
 Alk is C 1-7 alkylene; 
 R 11  is OR 10  or SR 10  , where R 10  is C 1-4 alkyl; and 
 R 12  and R 13  are each independently hydrogen, halogen, C 1-4 alkyl or C 1-4 alkoxy. 
 
     
     
       2. A compound of  claim 1 , having the structure: 
       
         
           
           
               
               
           
         
         wherein n is 3 and Y is ethylthio, n is 3 and Y is ethoxy, or n is 5 and Y is ethoxy, or a salt thereof. 
       
     
     
       3. The compound of  claim 1  wherein the salt is a pharmaceutically acceptable salt. 
     
     
       4. A composition comprising a compound of  claim 3 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier. 
     
     
       5. A method for the treatment of a human rhinovirus (HRV) infection in a respiratory tract of a mammal, comprising administering to the mammal an effective amount of a composition of  claim 4 .